|
|
Article: Accera Announces Peer-Reviewed Publication of the Results of its 90-Day Clinical Study of AC-1202 (Axona™ ) in Mild to Moderate Alzheimer's Disease.(Clinical report)
- Article from:
- Clinical Trials Week
- Article date:
- August 24, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system (CNS) disorders, announced publication of a scientific paper in the peer-reviewed journal Nutrition & Metabolism. The paper, entitled "Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial" suggests that daily administration of AC-1202 (Axona™) can help improve cognition and memory in patients with mild-to-moderate Alzheimer's disease (AD) (see also Alzheimer Disease).
"Accera has taken a novel approach to Alzheimer's therapy with the development of Axona," said Samuel ...